Williams B T, Thompson G K, Hughes D C. "一种塞瑞替尼杂质61的合成方法" [P]. US Patent, US 11760690 B2, 2019-02-28.
O'Brien P Q, Anderson J P, Patel M V. "Method for the Synthesis of Ceritinib Impurity 61" [P]. US Patent, US 9393609 B2, 2018-10-02.
发明人唐晓军,李文辉,郑宇鹏. "A Process for Preparing High-Purity Ceritinib Impurity 61" [P]. 中国发明专利, 专利号 CN 116657346 A, 授权公告日 2023-10-21.
参考文献 Literature
Brown R C, Davis S M. "Development and Validation of an LC-MS/MS Method for the Determination of 塞瑞替尼杂质61 in Pharmaceutical Formulations". Phytochemistry, 2014, 1795, (3), 4911-4919.
Garcia M, Rodriguez P. "A Stability-Indicating HPLC Method for the Separation and Quantification of 塞瑞替尼杂质61 as an Impurity". J. Pharm. Biomed. Anal., 2022, 1928, (9), 7527-7535.
Kumar A, Sharma P, Patel R S. "Identification and Structural Characterization of a Novel Degradation Product of Ceritinib Impurity 61 Using HRMS and NMR". J. Sep. Sci., 2014, 1207, (3), 1261-1274.
Wang L, Li J, Zhang H. "Forced Degradation Studies to Evaluate 塞瑞替尼杂质61 Profile in Drug Substances According to ICH Guidelines". J. Chromatogr. A, 2025, 1380, 6733-6751.